TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06320483

Intervention type: DEVICE
Intervention: Vibroacoustic device BARK VibroLUNG
Description: The BARK VibroLUNG vibroacoustic device is intended for the treatment and prevention of respiratory pathologies.~The BARK VibroLUNG vibroacoustic device with accessories is a medical device and is intended for the treatment of pathological conditions associated with obstructive and restrictive lung diseases in patients in medical institutions.~Field of application: physiotherapy of the chest organs, treatment and prevention of respiratory failure.~The therapeutic mechanism of action is due to three main effects: improved bronchial drainage, improved ventilation-perfusion ratios, and the lung opening maneuver.
Study: NCT06281483

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: platelet-rich plasma
Description: Under aseptic conditions, 20 mL of whole blood will be withdrawn from each patient and will be collected in the centrifuge tube prefilled with Anticoagulant Citrate Dextrose (1.5 mL each). A two-stage centrifugation process (double-spin method) will be employed for the preparation of PRP. The first spin is at 100 relative centrifugal force (RCF) (g) for 10 min, while the second spin is at 400 RCF for 10 min. PRP will be injected into the base of the ulcer and the surrounding skin. Group A: will receive treatment that will include PRP application, conventional debridement, and dressing coverage. Sessions will be repeated weekly for a maximum of eight sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: platelet-rich fibrin
Description: 20 ml blood will be drawn from each patient by venipuncture under aseptic precautions in four sterile glass tubes of 5-ml capacity without anticoagulant and immediately centrifuged. A single stage centrifugation process, that is (200 g for 8 min), has been found to produce a fibrin clot with the highest platelet and WBC count and highest overall cumulative growth factor yield. Group B: will receive treatment that will include PRF application, conventional debridement, and dressing coverage. Sessions will be repeated weekly for a maximum of eight sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical debridement, normal saline washing and dressing coverage
Description: Each patient will receive the same conventional debridement and dressing coverage (After opening the bandage, the ulcer will be irrigated with normal saline and will be prepared for debridement as required to remove dead tissues and hyperkeratotic skin. Then, a second wash with normal saline will be done to remove any debris), but without any PRP nor PRF application.
Study: NCT06501755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial alternating current stimulation (tACS)
Description: Transcrainal alternating current stimulation (tACS) is a non-invasive brain-stimulation where weak sinusoidal electric current with frequencies within the EEG-range is applied over electrodes on the scalp. In the study we use the DC-Stimulator MC, neuroConn, Ilmenau for the stimulation.The device is authorized as medical device for the application on humans in Germany with a CE-Identification. We use two circular (area each = ca. 7.07 cm\^2) and two ring-shaped (area each = 40 cm\^2) rubber electrodes. Impedances are kept \< 15 kOhm.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial alternating current stimulation (tACS)
Description: Transcrainal alternating current stimulation (tACS) is a non-invasive brain-stimulation where weak sinusoidal electric current with frequencies within the EEG-range is applied over electrodes on the scalp. In the study we use the DC-Stimulator MC, neuroConn, Ilmenau for the stimulation.The device is authorized as medical device for the application on humans in Germany with a CE-Identification. We use two circular (area each = ca. 7.07 cm\^2) and two ring-shaped (area each = 40 cm\^2) rubber electrodes. Impedances are kept \< 15 kOhm.
Study: NCT05294094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blended learning
Description: The blended learning course consists of two parts. The first part is an online course with case studies and instructional videos providing basic clinical diagnostic knowledge and the ability to conduct structured clinical interviews. In the second part, learners get to discuss the course content with a teacher, practice their interviewing skills with other students and make a transfer to a real face-to-face diagnostic situation with an actor simulating a patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: teaching format as usual
Description: The teaching format as usual represents the usual teaching of clinical diagnostic knowledge and the ability to conduct structured clinical interviews. Also in this intervention students also have the opportunity to discuss the course content with a teacher, practice their interviewing skills with other students and conduct a structured interview with an actor simulating a patient.
Study: NCT05943522

Intervention type: OTHER
Intervention: Asciminib
Description: There is no treatment allocation. Asciminib will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis
Study: NCT04889144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Participate in PLAN intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05947955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhu-pGSN
Description: Intravenous administration based on actual body weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: intravenous administration in the same volume as the active therapy
Study: NCT05119712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Tablets
Description: 500mg oral terbinafine or placebo daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Tablets
Description: 500mg oral terbinafine or placebo daily

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Testing
Description: Laboratory testing at screening, baseline, week 8, 16, 24 and 32.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Testing
Description: Laboratory testing at screening, baseline, week 8, 16, 24 and 32.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Testing
Description: Subjects with the potential to become pregnant will have a baseline urine pregnancy test prior to starting study drug.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Testing
Description: Subjects with the potential to become pregnant will have a baseline urine pregnancy test prior to starting study drug.
Study: NCT05493020

Intervention type: OTHER
Intervention: Questionnaires set
Description: At baseline, the children's demographics, disease-related data, characteristics of Mukbangwatching behavior, appetite, nutritional status, and quality of life data were collected. From the first day of radiotherapy or chemotherapy, 3 meals a day for 5 consecutive days were followed to track the children's appetite status and the characteristics of Mukbangwatching behavior. Their nutritional status and quality of life were tracked at the end of treatment or when they were discharged from the hospital.
Study: NCT06344078

Intervention type: PROCEDURE
Intervention: sigmoid resection and anastomosis / stoma
Description: intestinal resection and recostruction or creation of stoma
Study: NCT06042933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post operative early oral feeding
Description: To start oral feeding 6 hours after perforated peptic ulcer repairs

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional delayed oral Feeding Post-perforated Peptic Ulcer Repairs
Description: To start oral feeding after 48 hours
Study: NCT01675986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyzine
Description: 75 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose
Description: 4 g
Study: NCT04880577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TENOFOVIR ALAFENAMIDE FUMARATE 25 Mg ORAL TABLET [VEMLIDY]
Description: The study is designed to add on TAF to anti-CD20 therapies

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm
Study: NCT05273827

Intervention type: DRUG
Intervention: neoadjuvant immunotherapy
Description: Anti-PD-1 antibody was added to the conventional neoadjuvant chemotherapy.

Intervention type: DRUG
Intervention: Neoadjuvant chemotherapy
Description: Cis-platinum combined with paclitaxel or pemetrexed
Study: NCT06046261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACP board game for life
Description: The research subjects will be assigned to the experimental group or the control group according to their wishes. Those who are willing to participate the ACP board game will be assigned to the experimental group. The intervention time for each board game is around 2 hours. There are 60 cards in this ACP board game; the focus of the game is to know the participants' thoughts on the card options. Questionnaires need to be filled in before and after intervention.
Study: NCT04631029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study: NCT05639855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health Literacy Programme
Description: Mental Health Literacy Program. This program is part of the training of third-year students of the occupational therapy degree at the University of A Coruña. We will follow a mixed method following a sequential explanatory design. The quantitative part corresponds to a quasi-experimental study, where a comparison will be made between the phase before and after the students take the program. The qualitative part will comprise a phenomenological study to collect the knowledge acquired by the students after taking the program.
Study: NCT04623983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bonding tray
Description: Orthodontic bonding tray

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bonding tray
Description: Orthodontic bonding tray
Study: NCT04711707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community navigator
Description: All patients who consent to participate in the study will complete a pediatric social history tool to identify social needs. The intervention group will receive support through a community navigator to guide and understand appropriate services for their specific needs. This arm will receive guidance and bimonthly check-ins.

Intervention type: OTHER
Group type: OTHER
Intervention: Self-Navigation
Description: The control group will receive an electronic or paper copy of community resources that address the identified social needs.
Study: NCT06063109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THP-00101 (Dapagliflozin) 10mg
Description: Dapagliflozin 10mg Tablet / 5 days in period 1 and period 2 will be given to Arm A Dapagliflozin 10mg Tablet / 5 days in period 2 will be given to Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THP-00101 (Dapagliflozin) 10mg
Description: Dapagliflozin 10mg Tablet / 5 days in period 1 and period 2 will be given to Arm A Dapagliflozin 10mg Tablet / 5 days in period 2 will be given to Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THP-00102 (Telmisartan) 80mg
Description: Telmisartan 80mg Tablet / 5 days in period 1 and period 2 will be given to Arm B Telmisartan 80mg Tablet / 5 days in period 2 will be given to Arm A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THP-00102 (Telmisartan) 80mg
Description: Telmisartan 80mg Tablet / 5 days in period 1 and period 2 will be given to Arm B Telmisartan 80mg Tablet / 5 days in period 2 will be given to Arm A
Study: NCT05929690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-acupuncture
Description: Participants be taught to safely apply acupuncture bilaterally using traditional acupuncture needles to the acupuncture point Stomach 36. If deemed to be clinically appropriate by the acupuncturists, and if patients are willing and able, they will also be taught how to safely needle the acupuncture points Spleen 6 and/or Liver 3 (maximum of six points in total).
Study: NCT05493319

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Both groups will train three times a week, twice synchronously online and once asynchronously, considering a standardized exercise guideline. In all intervention sessions, conventional exercises will be guided by the standardized exercise guideline previously developed by the study team, for 4 weeks. Hypopresive, strength and resistance exercises group will receive static hypopressive exercise in supine position, with variant of arms in flexion, abduction and extension, consisting of 3 exercises at the end of the intervention with strength and resistance exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Both groups will train three times a week, twice synchronously online and once asynchronously, considering a standardized exercise guideline. In all intervention sessions, conventional exercises will be guided by the standardized exercise guideline previously developed by the study team, for 4 weeks. Hypopresive, strength and resistance exercises group will receive static hypopressive exercise in supine position, with variant of arms in flexion, abduction and extension, consisting of 3 exercises at the end of the intervention with strength and resistance exercises.
Study: NCT05702528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apollo Neuro
Description: The group will complete daily use of the Apollo Neuro, a wrist-worn consumer wellness device
Study: NCT04814693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoRotor® System (Interscope, Inc., Northbridge, MA USA),
Description: The EndoRotor System is intended for use in endoscopic procedures to resect and remove necrotic debris during DEN for WON. DEN with the EndoRotor System (study device) is considered to be standard of care therapy for patients with WON and not investigational.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional endoscopic devices (according to standards of care)
Description: Endoscopic devices used to perform conventional DEN will be chosen according to standard of care and Investigator preference.
Study: NCT05001347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ004309
Description: Antibody to CD73
Study: NCT05388539

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Theta Burst Stimulation
Description: 3 TBS sessions per day, with an offer of 1200 pulses per session and a 30-minute interval between sessions. This protocol will be applied to patients for 15 days, totaling 45 stimulation sessions. The stimulations will be directed to the left dorsolateral prefrontal cortex (F3 obtained by the Beam method) and will be performed in a Magventure MagPro R30 device.The stimulation will be delivered at 100% of the motor threshold and will last for 6 minutes.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Stimulation
Description: The placebo will consist of a sham stimulation activity. A noise generator, which makes the same noise as active stimulation, and a surface electrode placed over the patient's eyebrow, mimicking the tactile sensory effects of TBS. It will also occur three times a day, with a duration of 6 minutes. The interval time between procedures will be of 30 minutes. It will take place for the same 15 weekdays, totalizing 45 sham stimulations.
Study: NCT05469971

Intervention type: GENETIC
Intervention: KIR genotyping
Description: DNA extraction and KIR genotyping by KIR SSO Genotyping Test (One Lambda, Thermo Fisher, Monza, Italy).

Intervention type: GENETIC
Intervention: KIR genotyping
Description: DNA extraction and KIR genotyping by KIR SSO Genotyping Test (One Lambda, Thermo Fisher, Monza, Italy).

Intervention type: GENETIC
Intervention: KIR genotyping
Description: DNA extraction and KIR genotyping by KIR SSO Genotyping Test (One Lambda, Thermo Fisher, Monza, Italy).
Study: NCT06149234

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fruit leather on the tongue
Description: The patient holds a fruit leather strip on the tongue while being exposed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chewing gum strip
Description: The patient holds a banana-tasting gum strip on the tongue while being exposed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Celluloid matrix group
Description: The patient holds a celluloid matrix stirp gum strip on the tongue while being exposed.
Study: NCT06275503

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Screening invitation mode
Description: Cluster randomized study to compare mode of invitation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Screening invitation mode
Description: Cluster randomized study to compare mode of invitation
Study: NCT05386329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindset: Therapist-guided smartphone-delivered CBT
Description: All participants will receive the app-delivered CBT, including modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., activity scheduling), and mindfulness. Therapists will also conduct brief weekly virtual appointments with participants.
Study: NCT05945953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentive spirometer as visual feedback
Description: Incentive spirometer as deep breathing then UE movement in sitting: Frequency: 2 sets of 10x Intensity: Up to tolerance (hold breath for 2-4 secs). Time: Twice a week Type: Deep breathing exercise UE movement: Gentle ROMs (5 reps)~along with conventional Treatment; Passive stretching of spastic muscles, Strengthening of weak muscles using manual resistance, Diaphragmatic Breathing, Resisted Diaphragmatic Breathing (placing 5Ib sandbag on abdomen).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic breathing exercise (Mirror mediated therapy)
Description: Diaphragmatic breathing exercise (Mirror mediated therapy): In front of mirror deep breathing with UE movement in sitting: Frequency: 1 cycle of 10x Intensity: Up to tolerance. Time: 3 times per week. Type: Deep breathing exercise. UE movement: Gentle ROMs (5 reps).~along with conventional Treatment; Passive stretching of spastic muscles, Strengthening of weak muscles using manual resistance, Diaphragmatic Breathing, Resisted Diaphragmatic Breathing (placing 5Ib sandbag on abdomen).
Study: NCT06431061

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (omafilcon B)
Description: 15 minutes of daily wear.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (comfilcon A)
Description: 15 minutes of daily wear.
Study: NCT05409547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF 6 mg/d (single dose) will be given on the second day after chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-rhG-CSF
Description: PEG-rhG-CSF 6 mg/d (single dose) will be given on the second day after chemotherapy.
Study: NCT05648435

Intervention type: DIAGNOSTIC_TEST
Intervention: Lithium measures
Description: Measurements of lithium levels in blood and urine

Intervention type: DIAGNOSTIC_TEST
Intervention: Lithium measures
Description: Measurements of lithium levels in blood and urine
Study: NCT06276803

Intervention type: DIAGNOSTIC_TEST
Intervention: LINFU®
Description: Patients will undergo low intensity non-focused ultrasound excitation of the pancreas for a total of 15 minutes using a GE LOGIQ10 or other FDA approved, FDA cleared or FDA exempt ultrasound insonation. A contrast agent will be administered IV during the ultrasound insonation and the patient will also receive a dose of secretin. The pancreatic juice will then be collected for a total of 15 minutes.
Study: NCT06302218

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2% Injectable Solution
Description: iPACK block + Adductor Canal Block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2% Injectable Solution
Description: Erector Spinae Plane Block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: only spinal anesthesia
Study: NCT04901299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NERATINIB
Description: Neratinib will be given orally once daily on a continuous daily dosing schedule i.e., no break in dosing. Dosage per protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FULVESTRANT
Description: Fulvestrant will be given via injection every two weeks for the first 28-day cycle and every four weeks thereafter, dosage per protocol
Study: NCT06023979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full weight bearing
Description: Full weight bearing monitored with a bio-feedback insole

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Partial weight bearing
Description: Partial weight bearing monitored with a bio-feedback insole
Study: NCT05066256

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Left ventricular diastolic function
Description: Transthoracic echocardiography Mitral E/e'

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Inferior vena cava variation
Description: Inferior vena cava variation from ultrasound
Study: NCT06255457

Intervention type: PROCEDURE
Intervention: Mitral valve surgery
Description: Mitral valve repair or replacement of mitral regurgitation
Study: NCT05662423

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive Writing about Childbirth
Description: Participants will write repeatedly about their deepest emotions and thoughts related to their recent childbirth, focusing on the most stressful experiences.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Writing
Description: Participants will write repeatedly about neutral daily events/tasks not related to childbirth.
Study: NCT06093139

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic capsule
Description: probiotic capsule (composition same as described above - L. acidophilus FB0012, L. plantarum FB0015, and L. rhamnosus FB0047 encapsulated in acid-resistant capsules

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo consisted of the same capsules filled with potato starch